Antibody drug conjugates (ADCS) having enzymatically cleavable groups

US11478554B2 · kind B2 · utility

Assignees

• Bayer Pharma Aktiengesellschaft · DE
• BAYER HEALTHCARE LLC · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Dennis KIRCHHOFF · Berlin, DE
• Lisa DIETZ · Wuppertal, DE
• Christoph MAHLERT · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Stephan MÄRSCH · Cologne, DE
• Sandra BERNDT · Hohen Neuendorf, DE
• Anette SOMMER · Berlin, DE
• Stefanie HAMMER · Berlin, DE

Key dates

• Filing date: Sep 1, 2021
• Grant date: Oct 25, 2022
• Expiry date: Sep 1, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.